74 related articles for article (PubMed ID: 19081178)
41. A spiroligomer α-helix mimic that binds HDM2, penetrates human cells and stabilizes HDM2 in cell culture.
Brown ZZ; Akula K; Arzumanyan A; Alleva J; Jackson M; Bichenkov E; Sheffield JB; Feitelson MA; Schafmeister CE
PLoS One; 2012; 7(10):e45948. PubMed ID: 23094022
[TBL] [Abstract][Full Text] [Related]
42. Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 function.
Muret J; Hasmim M; Stasik I; Jalil A; Mallavialle A; Nanbakhsh A; Lacroix L; Billot K; Baud V; Thiery J; Vielh P; Terrier P; Wiels J; Vassilev L; Lecesne A; Bonvalot S; Chouaib S
PLoS One; 2012; 7(6):e38808. PubMed ID: 22719951
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic potential of p53 reactivation in cervical cancer.
Zhao X; Sun W; Ren Y; Lu Z
Crit Rev Oncol Hematol; 2021 Jan; 157():103182. PubMed ID: 33276182
[TBL] [Abstract][Full Text] [Related]
44. Characterization and Molecular Mechanism of Peptide-Conjugated Gold Nanoparticle Inhibiting p53-HDM2 Interaction in Retinoblastoma.
Kalmodia S; Parameswaran S; Ganapathy K; Yang W; Barrow CJ; Kanwar JR; Roy K; Vasudevan M; Kulkarni K; Elchuri SV; Krishnakumar S
Mol Ther Nucleic Acids; 2017 Dec; 9():349-364. PubMed ID: 29246314
[TBL] [Abstract][Full Text] [Related]
45. The Expression and Function of NUMB in Endometrial Cancer and the Interaction with HDM2 and P53.
Wang C; Feng W; Zhang C
J Cancer; 2015; 6(10):1030-40. PubMed ID: 26366217
[TBL] [Abstract][Full Text] [Related]
46. PNC27 anticancer peptide as targeting ligand significantly improved antitumor efficacy of Doxil in HDM2-expressing cells.
Darban SA; Badiee A; Jaafari MR
Nanomedicine (Lond); 2017 Jun; 12(12):1475-1490. PubMed ID: 28565974
[TBL] [Abstract][Full Text] [Related]
47. Ferroptosis suppressed the growth of melanoma that may be related to DNA damage.
Wang Z; Jin D; Ma D; Ji C; Wu W; Xu L; Zhang L
Dermatol Ther; 2019 Jul; 32(4):e12921. PubMed ID: 30977962
[No Abstract] [Full Text] [Related]
48. Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.
Ma Y; Lahue BR; Gibeau CR; Shipps GW; Bogen SL; Wang Y; Guo Z; Guzi TJ
ACS Med Chem Lett; 2014 May; 5(5):572-5. PubMed ID: 24900882
[TBL] [Abstract][Full Text] [Related]
49. Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097.
Jeay S; Gaulis S; Ferretti S; Bitter H; Ito M; Valat T; Murakami M; Ruetz S; Guthy DA; Rynn C; Jensen MR; Wiesmann M; Kallen J; Furet P; Gessier F; Holzer P; Masuya K; Würthner J; Halilovic E; Hofmann F; Sellers WR; Graus Porta D
Elife; 2016 Nov; 5():. PubMed ID: 27852439
[No Abstract] [Full Text] [Related]
50. DNA-Dependent Protein Kinase Inhibitor Peposertib Potentiates the Cytotoxicity of Topoisomerase II Inhibitors in Synovial Sarcoma Models.
Revia S; Budzinska MA; Bogatyrova O; Neumann F; Zimmermann A; Amendt C; Albers J
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201616
[TBL] [Abstract][Full Text] [Related]
51. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
52. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
53. STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells.
Liao XH; Xiang Y; Yu CX; Li JP; Li H; Nie Q; Hu P; Zhou J; Zhang TC
Oncotarget; 2017 Feb; 8(9):15763-15774. PubMed ID: 28178652
[TBL] [Abstract][Full Text] [Related]
54. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
55. SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.
Minami Y; Kohsaka S; Tsuda M; Yachi K; Hatori N; Tanino M; Kimura T; Nishihara H; Minami A; Iwasaki N; Tanaka S
Cancer Sci; 2014 Sep; 105(9):1152-9. PubMed ID: 24989082
[TBL] [Abstract][Full Text] [Related]
56. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.
Przybyl J; Jurkowska M; Rutkowski P; Debiec-Rychter M; Siedlecki JA
Sarcoma; 2012; 2012():249219. PubMed ID: 22550415
[TBL] [Abstract][Full Text] [Related]
57. Targeting the p53 Pathway in Ewing Sarcoma.
Neilsen PM; Pishas KI; Callen DF; Thomas DM
Sarcoma; 2011; 2011():746939. PubMed ID: 21197471
[TBL] [Abstract][Full Text] [Related]
58. Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction.
D'Arcy P; Ryan BA; Brodin B
Cancer Lett; 2009 Mar; 275(2):285-92. PubMed ID: 19081178
[TBL] [Abstract][Full Text] [Related]
59. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
60. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha.
Lee YM; Lim JH; Chun YS; Moon HE; Lee MK; Huang LE; Park JW
Carcinogenesis; 2009 Oct; 30(10):1768-75. PubMed ID: 19696166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
